Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 1;160(12):1297-1303.
doi: 10.1001/jamadermatol.2024.3584.

Hidradenitis Suppurativa and Maternal and Offspring Outcomes

Kaiyang Li  1 , Vincent Piguet  2 , David Croitoru  2 , Shu Qin Wei  3   4 , Émilie Brousseau  3   5 , Elizabeth O'Brien  6 , Nathalie Auger  3   5   7   8
Affiliations

Hidradenitis Suppurativa and Maternal and Offspring Outcomes

Kaiyang Li et al. JAMA Dermatol. .

Erratum in

  • Error in the Results Section.
    [No authors listed] [No authors listed] JAMA Dermatol. 2025 Mar 1;161(3):342. doi: 10.1001/jamadermatol.2024.6382. JAMA Dermatol. 2025. PMID: 39841457 Free PMC article. No abstract available.

Abstract

Importance: Hidradenitis suppurativa (HS) is associated with morbidity in persons of reproductive age, but the effect on maternal and offspring outcomes is understudied.

Objective: To determine the association of HS with pregnancy outcomes and maternal and child morbidity in the long term.

Design, setting, and participants: This population-based longitudinal cohort study with up to 16 years of follow-up took place between 2006 and 2022 in Quebec, Canada. .

Exposure: Maternal HS.

Main outcomes and measures: Outcomes included hypertensive disorders of pregnancy, gestational diabetes, and other birth outcomes as well as the long-term risk of hospitalization up to 16 years after delivery. The study used adjusted log-binomial and Cox proportional hazards regression models to estimate the association between maternal HS and pregnancy outcomes or hospitalization following pregnancy. Outcomes in both mothers and offspring were assessed.

Results: There were 1 324 488 deliveries during the study, including 1332 (0.1%) among mothers with HS. Compared with patients without HS, patients with HS had a greater risk of hypertensive disorders of pregnancy (risk ratio [RR], 1.55 [95% CI, 1.29-1.87]), gestational diabetes (RR, 1.61 [95% CI, 1.40-1.85]), and severe maternal morbidity (RR, 1.38 [95% CI, 1.03-1.84]). In neonates, maternal HS was associated with risk of preterm birth (RR, 1.28 [95% CI, 1.07-1.53]) and birth defects (RR, 1.29 [95% CI, 1.07-1.56]). In the long term, HS was associated with 2.29 times the risk of maternal hospitalization (95% CI, 2.07-2.55) and 1.31 times the risk of childhood hospitalization (95% CI, 1.18-1.45), including hospitalization for respiratory, metabolic, psychiatric, and immune-related morbidity over time.

Conclusions and relevance: This cohort study found that HS is associated with adverse maternal and offspring outcomes in the peripartum period and in the long term. Early detection and management of HS may help mitigate these outcomes.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Piguet reported receiving grants from AbbVie, Bausch Health, Celgene, Eli Lilly, Incyte, Janssen, LEO Pharma, L'Oréal, Novartis, Organon, Pfizer, Sandoz, Amgen, Boehringer Ingelheim, and Bristol Myers Squibb outside the submitted work; receiving payment or honoraria for speaking engagements from Sanofi China; participating on advisory boards for LEO Pharma, Novartis, Sanofi, and Union Therapeutics; and receiving an equipment donation from L'Oréal. Dr Auger reported receiving grants from Canadian Institutes of Health Research and a career award from Fonds de recherche du Québec-Santé (296785) during the conduct of the study. No other disclosures were reported.

References

    1. Garg A, Kirby JS, Lavian J, Lin G, Strunk A. Sex- and age-adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States. JAMA Dermatol. 2017;153(8):760-764. doi: 10.1001/jamadermatol.2017.0201 - DOI - PMC - PubMed
    1. Saunte DML, Jemec GBE. Hidradenitis suppurativa: advances in diagnosis and treatment. JAMA. 2017;318(20):2019-2032. doi: 10.1001/jama.2017.16691 - DOI - PubMed
    1. Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2020;82(5):1045-1058. doi: 10.1016/j.jaad.2019.08.090 - DOI - PubMed
    1. Seivright JR, Villa NM, Grogan T, et al. Impact of pregnancy on hidradenitis suppurativa disease course: a systematic review and meta-analysis. Dermatology. 2022;238(2):260-266. doi: 10.1159/000517283 - DOI - PMC - PubMed
    1. Fitzpatrick L, Hsiao J, Tannenbaum R, Strunk A, Garg A. Adverse pregnancy and maternal outcomes in women with hidradenitis suppurativa. J Am Acad Dermatol. 2022;86(1):46-54. doi: 10.1016/j.jaad.2021.06.023 - DOI - PubMed

MeSH terms